Cannabidiol (Epidiolex) vs Cannabidiol (JZP926)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: cannabinoid · full Epilepsy pipeline

Cannabidiol (Epidiolex)

Marketed by Jazz Pharmaceuticals and partners

Approved in Epilepsysmall molecule
Partial signal

NCT02224573 · Phase 3 · completed

This is a genuine open-label extension trial: the title explicitly states 'Open Label Extension Study,' and eligibility required participants to have completed the treatment phase of the prior randomized, double-blind, placebo-controlled core studies (NCT02091206, NCT02091375, NCT02224703, NCT02224560, NCT02224690). It used a single group of 681 participants with no randomization, no blinding, and no comparator arm, so it cannot provide comparative evidence on its own. The primary outcomes were mostly safety measures plus descriptive changes in seizure frequency, and no inferential statistical comparison was conducted.

Next expected readout: August 2027 · NCT05044819 (registry estimate)

Reported efficacy

Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1) (met)

Result source: NCT02544763

Cannabidiol (JZP926)

Developed by Jazz Pharmaceuticals

Phase 2/3 in Epilepsysmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT07723963 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCannabidiol (Epidiolex)Cannabidiol (JZP926)
Seizure frequency, % change-47.3% vs -29.7%−17.6 vs placebo20 mg/kg/Day · wk 14.1 · n 67NCT02224703
4 other results
  • -41.2% vs -13.7% 20 mg/kg/day · wk 14.14 · n 86 · Phase 3 · secondary NCT02224690
  • -38.4% vs -18.5% 20 mg/kg/day · wk 14.14 · n 76 · Phase 3 · secondary NCT02224560
  • -56.4% vs -29.7% 10 mg/kg/Day · wk 14.1 · n 66 · Phase 3 · secondary NCT02224703
  • -36.4% vs -18.5% 10 mg/kg/day · wk 14.14 · n 73 · Phase 3 · secondary NCT02224560
—Trial running · NCT07723963
50% responder rate—Not posted · NCT02318602—Trial running · NCT07723963
Seizure freedom—Not posted · NCT02318602—Trial running · NCT07723963

Seizure frequency, % change

Cannabidiol (Epidiolex)
-47.3% vs -29.7%−17.6 vs placebo20 mg/kg/Day · wk 14.1 · n 67NCT02224703
4 other results
  • -41.2% vs -13.7% 20 mg/kg/day · wk 14.14 · n 86 · Phase 3 · secondary NCT02224690
  • -38.4% vs -18.5% 20 mg/kg/day · wk 14.14 · n 76 · Phase 3 · secondary NCT02224560
  • -56.4% vs -29.7% 10 mg/kg/Day · wk 14.1 · n 66 · Phase 3 · secondary NCT02224703
  • -36.4% vs -18.5% 10 mg/kg/day · wk 14.14 · n 73 · Phase 3 · secondary NCT02224560
Cannabidiol (JZP926)
—Trial running · NCT07723963

50% responder rate

Cannabidiol (Epidiolex)
—Not posted · NCT02318602
Cannabidiol (JZP926)
—Trial running · NCT07723963

Seizure freedom

Cannabidiol (Epidiolex)
—Not posted · NCT02318602
Cannabidiol (JZP926)
—Trial running · NCT07723963
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Cannabidiol (JZP926): no structured comparison results are available for Epilepsy.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cannabidiol (Epidiolex): 4 of 4 rows · Cannabidiol (JZP926): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCannabidiol (Epidiolex)
Dropout rate
46%Dravet Syndromea
NCT02224573 · Phase 3 · monotherapy
show 20 more results
33.6%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · monotherapy
82.3%
NCT02544750 · Phase 3 · monotherapy
14.8%20 mg/kg/day
NCT02091375 · Phase 3
16.3%20 mg/kg/day
NCT02224690 · Phase 3
11.8%20 mg/kg/day
NCT02224560 · Phase 3
2.7%10 mg/kg/day
NCT02224560 · Phase 3
16.4%50 mg/kg/Day
NCT02544763 · Phase 3
13.3%25 mg/kg/Day
NCT02544763 · Phase 3
—Cannabidiol OS
NCT02954887 · Phase 3 · registry result, not featured evidence
77.8%GWP42003-P OS
NCT02954887 · Phase 3 · registry result, not featured evidence
0%Cohort 1: GWP42003-P OS
NCT02953548 · Phase 3 · registry result, not featured evidence
0%Cohort 2: GWP42003-P OS
NCT02953548 · Phase 3 · registry result, not featured evidence
9%20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
4.5%10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
12.5%20 mg/kg/Day
NCT02565108 · Phase 2 · registry result, not featured evidence
11.1%20 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
12.5%10 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
0%5 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
41.3%
NCT02700412 · Phase 1 · registry result, not featured evidence
42.7%
NCT02695537 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
8.3%Dravet Syndromea
NCT02224573 · Phase 3 · monotherapy
show 20 more results
10.4%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · monotherapy
6.5%
NCT02544750 · Phase 3 · monotherapy
13.1%20 mg/kg/day
NCT02091375 · Phase 3
9.3%20 mg/kg/day
NCT02224690 · Phase 3
5.3%20 mg/kg/day
NCT02224560 · Phase 3
1.4%10 mg/kg/day
NCT02224560 · Phase 3
11%50 mg/kg/Day
NCT02544763 · Phase 3
10.7%25 mg/kg/Day
NCT02544763 · Phase 3
—Cannabidiol OS
NCT02954887 · Phase 3 · registry result, not featured evidence
—GWP42003-P OS
NCT02954887 · Phase 3 · registry result, not featured evidence
—Cohort 1: GWP42003-P OS
NCT02953548 · Phase 3 · registry result, not featured evidence
—Cohort 2: GWP42003-P OS
NCT02953548 · Phase 3 · registry result, not featured evidence
7.5%20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
0%10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
6.3%20 mg/kg/Day
NCT02565108 · Phase 2 · registry result, not featured evidence
0%20 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
12.5%10 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
0%5 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
7.5%
NCT02700412 · Phase 1 · registry result, not featured evidence
3.4%
NCT02695537 · Phase 1 · registry result, not featured evidence
Serious AEs
42.2%Dravet Syndromea
NCT02224573 · Phase 3 · monotherapy
show 20 more results
42.9%Lennox-Gastaut Syndrome
NCT02224573 · Phase 3 · monotherapy
24%
NCT02544750 · Phase 3 · monotherapy
16.4%20 mg/kg/day
NCT02091375 · Phase 3
23.3%20 mg/kg/day
NCT02224690 · Phase 3
—20 mg/kg/day
NCT02224560 · Phase 3
—10 mg/kg/day
NCT02224560 · Phase 3
13.7%50 mg/kg/Day
NCT02544763 · Phase 3
21.3%25 mg/kg/Day
NCT02544763 · Phase 3
22.2%Cannabidiol OS
NCT02954887 · Phase 3 · registry result, not featured evidence
—GWP42003-P OS
NCT02954887 · Phase 3 · registry result, not featured evidence
—Cohort 1: GWP42003-P OS
NCT02953548 · Phase 3 · registry result, not featured evidence
—Cohort 2: GWP42003-P OS
NCT02953548 · Phase 3 · registry result, not featured evidence
24.6%20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
20.3%10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence
6.3%20 mg/kg/Day
NCT02565108 · Phase 2 · registry result, not featured evidence
11.1%20 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
25%10 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
10%5 mg/kg/day
NCT02091206 · Phase 2 · registry result, not featured evidence
17.5%
NCT02700412 · Phase 1 · registry result, not featured evidence
16.9%
NCT02695537 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
diarrhoea 42.2%
pyrexia 37.1%
decreased appetite 31.4%
NCT02224573 · Phase 3 · monotherapy
show 15 more results
diarrhoea 37.7%
pyrexia 33.6%
convulsion 32.8%
NCT02224573 · Phase 3 · monotherapy
diarrhoea 57.3% (placebo 40.3%)
decreased appetite 32% (placebo 18.5%)
somnolence 32% (placebo 12.1%)
NCT02544750 · Phase 3 · monotherapy
20 mg/kg/day
diarrhoea 31.1% (placebo 10.2%)
somnolence 31.1% (placebo 10.2%)
decreased appetite 26.2% (placebo 5.1%)
NCT02091375 · Phase 3
20 mg/kg/day
diarrhoea 18.6% (placebo 8.2%)
somnolence 14% (placebo 9.4%)
decreased appetite 12.8% (placebo 2.4%)
NCT02224690 · Phase 3
50 mg/kg/Day
diarrhoea 54.8% (placebo 25%)
somnolence 26% (placebo 9.2%)
decreased appetite 23.3% (placebo 11.8%)
NCT02544763 · Phase 3
25 mg/kg/Day
diarrhoea 30.7% (placebo 25%)
decreased appetite 20% (placebo 11.8%)
pyrexia 18.7% (placebo 7.9%)
NCT02544763 · Phase 3
upper respiratory tract congestion 33.3%
anaemia 22.2%
blood triglycerides increased 22.2%
NCT02954887 · Phase 3 · registry result, not featured evidence
20 mg/kg/Day
decreased appetite 27.5% (placebo 16.9%)
diarrhoea 26.1% (placebo 12.3%)
somnolence 23.2% (placebo 13.8%)
NCT02224703 · Phase 3 · registry result, not featured evidence
10 mg/kg/Day
pyrexia 23.4% (placebo 16.9%)
somnolence 21.9% (placebo 13.8%)
diarrhoea 17.2% (placebo 12.3%)
NCT02224703 · Phase 3 · registry result, not featured evidence
20 mg/kg/Day
diarrhoea 37.5% (placebo 25%)
nausea 18.8% (placebo 0%)
vomiting 18.8% (placebo 0%)
NCT02565108 · Phase 2 · registry result, not featured evidence
20 mg/kg/day
decreased appetite 44.4% (placebo 0%)
abdominal pain upper 22.2% (placebo 0%)
sedation 22.2% (placebo 0%)
NCT02091206 · Phase 2 · registry result, not featured evidence
10 mg/kg/day
somnolence 37.5% (placebo 14.3%)
coordination abnormal 12.5% (placebo 0%)
decreased appetite 12.5% (placebo 0%)
NCT02091206 · Phase 2 · registry result, not featured evidence
5 mg/kg/day
abnormal behaviour 30% (placebo 0%)
pyrexia 30% (placebo 0%)
ataxia 20% (placebo 0%)
NCT02091206 · Phase 2 · registry result, not featured evidence
diarrhea 66.3%
sedation 18.8%
weight loss 17.5%
NCT02700412 · Phase 1 · registry result, not featured evidence
sedation 43.8%
diarrhea 34.8%
depression/mood issues 14.6%
NCT02695537 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cannabidiol (Epidiolex)

Drop Seizure Frequency -59.4% (n=366) @ 60wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT02224573 · Phase 3 · monotherapy
show 3 more results
-69.4% (n=366) @ 108wk
NCT02224573 · Phase 3 · monotherapy
-70.8% (n=366) @ 156wk
NCT02224573 · Phase 3 · monotherapy
-68.7% (n=366) @ 216wk
NCT02224573 · Phase 3 · monotherapy
Drop Seizure Frequency -59.4% (n=366)
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Last 12 weeks
NCT02224573 · Phase 3 · monotherapy
Convulsive Seizure Frequency -52.9% (n=315) @ 60wk
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
NCT02224573 · Phase 3 · monotherapy
show 4 more results
-64.3% (n=315) @ 108wk
NCT02224573 · Phase 3 · monotherapy
-69.4% (n=315) @ 156wk
NCT02224573 · Phase 3 · monotherapy
-72.3% (n=315) @ 216wk
NCT02224573 · Phase 3 · monotherapy
-55.6% (n=315) @ 264wk
NCT02224573 · Phase 3 · monotherapy
Convulsive Seizure Frequency -40% (n=315)
percent change · % of baseline
Extension (open-label)
No placebo or comparator arm
Last 12 weeks
NCT02224573 · Phase 3 · monotherapy
Seizure 50% 34.3% (n=315) @ 60wk
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT02224573 · Phase 3 · monotherapy · converted to % from 108 Participants as posted
show 8 more results
46.2% (n=366) @ 60wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 169 Participants as posted
23.2% (n=315) @ 108wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 73 Participants as posted
40.4% (n=366) @ 108wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 148 Participants as posted
15.2% (n=315) @ 156wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 48 Participants as posted
35% (n=366) @ 156wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 128 Participants as posted
2.2% (n=315) @ 216wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 7 Participants as posted
3.3% (n=366) @ 216wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 12 Participants as posted
0.6% (n=315) @ 264wk*
NCT02224573 · Phase 3 · monotherapy · converted to % from 2 Participants as posted
Seizure 50% 48.6% (n=315)
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
Last 12 Weeks
NCT02224573 · Phase 3 · monotherapy · converted to % from 153 Participants as posted
show 1 more result
51.4% (n=366)*
Last 12 Weeks
NCT02224573 · Phase 3 · monotherapy · converted to % from 188 Participants as posted
CGIC SGIC 3.2 vs 3.3 placebo score
absolute value · score
Extension (open-label)
Combined Caregiver and Subjects
NCT02544750 · Phase 3 · monotherapy
Convulsive Seizure Frequency -38.94% (n=61) vs -13.29% (n=59) placebo @ 14.1wk20 mg/kg/day
percent change · % of baseline
NCT02091375 · Phase 3
show 2 more results
-45.7% (n=67) vs -26.9% (n=65) placebo @ 14.1wk*20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence · converted to % from 45.7 percentage reduction as posted
-48.7% (n=66) vs -26.9% (n=65) placebo @ 14.1wk*10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence · converted to % from 48.7 percentage reduction as posted
Convulsive Seizure 50 % 42.6% (n=61) vs 27.1% (n=59) placebo @ 14.1wk20 mg/kg/day
responder rate · % of participants
NCT02091375 · Phase 3 · converted to % from 26 Participants as posted
show 2 more results
49.3% (n=67) vs 26.2% (n=65) placebo @ 14.1wk*20 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
43.9% (n=66) vs 26.2% (n=65) placebo @ 14.1wk*10 mg/kg/Day
NCT02224703 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
Non-Convulsive Seizure Frequency -40.16% (n=37) vs -34.69% (n=41) placebo @ 14.1wk20 mg/kg/day
percent change · % of baseline
NCT02091375 · Phase 3
Rescue Medication Use 59% (n=61) vs 69.5% (n=59) placebo @ 14.1wk20 mg/kg/day
event count · % of participants
NCT02091375 · Phase 3 · converted to % from 36 Participants as posted
Sleep Disturbance NRS -0.7 vs -0.3 placebo score @ 14.1wk20 mg/kg/day
absolute change · score
NCT02091375 · Phase 3

+ 17 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cannabidiol (Epidiolex)'s landscape · Cannabidiol (JZP926)'s landscape